Caliper Life Sciences, Inc. (CALP) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)
Depreciation and amortization	7.45M
Non-cash in-process research and development charge
Stock-based compensation expense, net	2.9M
Gain on divestiture	0
Non-cash restructuring charge, net	2.26M
Foreign currency exchange losses	-74K
Accounts receivable	2.59M
Inventories	-2.98M
Prepaid expenses and other current assets	-749K
Accounts payable and other accrued liabilities	228K
Accrued compensation	-678K
Deferred revenue and customer deposits
Other noncurrent liabilities	-487K
Payments of accrued restructuring obligations, net	-2.34M
Net cash from operating activities
Purchases of marketable securities	-8.61M
Proceeds from sales of marketable securities	1.26M
Proceeds from maturities of marketable securities	6.8M
Other assets	125K
Purchases of property and equipment	-1.85M
Proceeds from divestiture	0
Net cash from investing activities
Borrowings under credit facility	0
Payments of credit facility and other obligations	0
Payments of capital leases and other obligations	-444K
Proceeds from issuance of common stock	11.63M
Net cash from financing activities
Effect of exchange rates on changes in cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period	24.61M
Cash and cash equivalents at end of period	36.53M

Entities mentioned with CALP

View All Entities